Last Wednesday, at a hearing held by the House Appropriations Committee, U.S. Food and Drug Administration (“FDA”) Commissioner Scott Gottlieb revealed the FDA’s plan to conduct public hearings on cannabidiol (“CBD”) starting in April. Acknowledging the legalization of hemp and hemp-derived products … Read more about FDA Plans Public Hearing on Ingestible CBD Products
Securing federal trademark protection for products derived from industrial hemp has proven to be a challenge for many in the industry. The United States Patent and Trademark Office (the “USPTO) categorically denies any trademark application that is submitted for an “illegal” product or service.1 Up … Read more about The Agricultural Improvement Act of 2018 & Federal Trademarks
Epidolex, the first FDA-approved cannabis-based medication, is now available via prescription in all US states. Produced by GW Pharmaceuticals, the drug received approval by the US Food and Drug Administration (FDA) in June, followed by a narrow rescheduling by the US Drug … Read more about Epidiolex Now Available Across US
The Drug Enforcement Administration (DEA) has rescheduled the cannabidiol (CBD) based drug Epidolex, but limited the rescheduling to exclude all CBD products. Epidiolex will be scheduled at Schedule 5, the lowest level of drug scheduling under the Controlled Substances Act (CSA). Epidiolex, … Read more about DEA Reschedules CBD-Based Epidiolex
In a blow to hemp-derived cannabidiol (CBD) product manufacturers who intend to use CBD as a food additive, the California Department of Public Health (CDPH), in conjunction with the California Food and Drug Branch (FDB), has released a clarification document titled: "FAQ - Industrial Hemp and … Read more about CBD in Food? California Says No Way, (San) Jose.